0001564590-21-010712.txt : 20210304 0001564590-21-010712.hdr.sgml : 20210304 20210304070521 ACCESSION NUMBER: 0001564590-21-010712 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210304 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210304 DATE AS OF CHANGE: 20210304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 21712540 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 8-K 1 eypt-8k_20210304.htm 8-K eypt-8k_20210304.htm
false 0001314102 0001314102 2021-03-04 2021-03-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 4, 2021

 

EyePoint Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

 

000-51122

 

26-2774444

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

480 Pleasant Street

Watertown, MA 02472

(Address of Principal Executive Offices, and Zip Code)

(617) 926-5000

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of

each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001

 

EYPT

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On March 4, 2021, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2020 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto. 

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

  

Description

99.1

  

Press Release of EyePoint Pharmaceuticals, Inc., dated March 4, 2021

104

 

Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EyePoint Pharmaceuticals, Inc.

 

 

Date: March 4, 2021

 

By:

 

/s/ George O. Elston

 

 

Name:

 

George O. Elston

 

 

Title

 

Chief Financial Officer and Head of Corporate Development

 

 

 EX-99.1 2 eypt-ex991_6.htm EX-99.1 eypt-ex991_6.htm

 

Exhibit 99.1

 

EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Corporate Developments

- $115.1 million follow-on financing completed in February 2021

- First patient dosed in Phase 1 clinical trial with EYP-1901 in January 2021

- $16.5 million monetization of ILUVIEN Royalty with $15 million applied to reduction in debt obligations in December 2020

$15.7 million equity investment by Asia partner Ocumension Therapeutics in December 2020

- Total revenues for Full Year 2020 of $34.4 million including net product revenues of $20.8 million

 - Management to host a conference call and webcast today at 8:30 AM ET –

 

WATERTOWN, Mass., March 4, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced financial results for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate developments.

“This year was transformative for EyePoint, across all clinical, financial and commercial fronts, despite the impact of COVID-19 on our business. In December 2020, we filed the IND for EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration (wet AMD), and the first patient was dosed in January. We are excited about the potential for EYP-1901 to dramatically transform the treatment of wet AMD offering patients the opportunity for fewer treatments and improved results,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “On the commercial front, despite the challenges of COVID-19 with closures in the earlier part of the year, we were pleased to see a return of customer demand of our commercial products to near pre-COVID levels in the second half of 2020.”

Ms. Lurker continued, “In addition to the advancement of EYP-1901, we have made tremendous progress to improve our balance sheet, including a recent upsized follow-on stock offering with $115.1 million of gross proceeds and a $16.5 million royalty monetization with $15 million applied to reduce outstanding debt obligations.”

 

Corporate Update

 

•

In February 2021, the Company completed an upsized underwritten public offering of 10,465,000 shares of its common stock at a public offering price of $11.00 per share, including the exercise in full by the underwriters of their option to purchase up to 1,365,000 additional shares of common stock. The gross proceeds of the offering to the Company were

 

 

 

approximately $115.1 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. Cowen and Guggenheim acted as joint book-running managers for the offering.

 

•

In December, Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK), made a $15.7 million equity investment in EyePoint, purchasing approximately 3.01 million shares of EyePoint’s common stock.

 

•

Also in December, EyePoint announced a royalty monetization agreement with SWK Holdings Corporation for royalties payable to EyePoint under its license agreement with Alimera Sciences, Inc. for ILUVIEN®.  EyePoint received a one-time $16.5 million payment from SWK in exchange for the rights to future royalties payable to EyePoint from the Alimera agreement. $15 million of the net proceeds from this transaction were applied toward debt obligations with CRG Servicing LLC (CRG). The remaining $1.5 million will be used to advance product pipeline programs.

Commercial Performance in Fourth Quarter 2020

 

•

Net product revenue for YUTIQ and DEXYCU was $4.0 million and $2.7 million, respectively.

 

 

•

Customer demand of approximately 6,200 units for DEXYCU and approximately 500 units for YUTIQ, increases of 30% and 10%, respectively, over Q3 2020.

 

 

•

DEXYCU commercial alliance partner, ImprimisRx®, began driving volume through their experienced cataract surgery field force, materially adding to Q4 customer demand.

 

R&D Highlights

 

•

In January 2021, the Company announced that the first patient was dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet AMD. EYP-1901 leverages a bioerodible formulation of the Company’s proprietary Durasert® drug delivery technology platform that has been used in four FDA-approved products, including EyePoint’s YUTIQ® for chronic non-infectious uveitis affecting the posterior segment of the eye.

 

 

•

In November, positive data for YUTIQ® and DEXYCU® were featured in four presentations at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Statistically significant efficacy results from the second Phase 3 trial of YUTIQ were presented and post-cataract surgery inflammatory reduction data from a multicenter retrospective study of real-world usage of DEXYCU were also presented.

 

Review of Results for Fourth Quarter Ended December 31, 2020
For the three months ended December 31, 2020, total net revenue was $7.1 million compared to $8.6 million for the three months ended December 31, 2019. Net product revenue for the three months ended December 31, 2020 was $6.7 million, with $4.0 million for YUTIQ and $2.7 million for DEXYCU, compared to net product revenue for three months ended December 31, 2019 of $7.9 million with $4.8

 

 

million for YUTIQ and $3.1 million for DEXYCU. Net product revenue represents product purchased by EyePoint’s distributors whereas customer demand represents purchases of product by physician practices and ASCs from EyePoint’s distributors.

Net revenue from licenses, royalties and collaborations for the three months ended December 31, 2020 totaled $0.4 million compared to $0.7 million in the corresponding quarter in 2019.

Operating expenses for the three months ended December 31, 2020 totaled $19.9 million compared to $17.6 million in the prior year period. This increase was driven by a $1.6 million increase in G&A expense, a $1.1 million increase in cost of sales and a $1.1 million increase in R&D expense being partially offset by a $1.6 million reduction in sales and marketing expense. Non-operating expense, net, for the three months ended December 31, 2020 totaled $2.7 million of net interest expense. Net loss for the three months ended December 31, 2020 was $15.5 million, or $1.07 per share, compared to a net loss of $10.4 million, or $0.98 per share, for the prior year quarter.

Review of Results for the Full Year Ended December 31, 2020
For the full year ended December 31, 2020, total net revenue was $34.4 million compared to $20.4 million for the full year ended December 31, 2019. Net product revenue for the full year ended December 31, 2020 was $20.8 million, compared to net product revenues for the full year ended December 31, 2019 of $16.8 million.

Net revenue from royalties and collaborations for the full year ended December 31, 2020 totaled $13.6 million compared to $3.5 million in the corresponding period in 2019.

Operating expenses for the full year ended December 31, 2020 totaled $71.7 million versus $68.2 million in the prior year period. This increase was primarily due to a $3.1 million increase in cost of sales, a $2.8 million increase in G&A expense, a $2.1 million increase in R&D expense partially offset by a $4.5 million decrease in sales and marketing expense. Non-operating expense, net, totaled $8.1 million and net loss was $45.4 million, or $3.54 per share, compared to a net loss of $56.8 million, or $5.44 per share, for the prior year period.

Cash and cash equivalents at December 31, 2020 totaled $44.9 million compared to $22.2 million at December 31, 2019.

Financial Outlook
We expect the cash on hand at December 31, 2020 together with the approximate $108 million of net proceeds from the February 2021 public stock offering and expected net cash inflows from our product sales will enable us to fund our current and planned operations through the second quarter of 2022.

Conference Call Information
EyePoint will host a conference call today, at 8:30 AM ET to discuss the results for the fourth quarter and full year ended December 31, 2020 and recent operational developments. To access the conference call, please dial (877-303-5828) from the U.S. and Canada or (631)-813-4828 (international) at least 10 minutes prior to the start time and refer to conference ID 1261618. A live webcast will be available on the Investor Relations section of the corporate website at http://www.eyepointpharma.com. A replay of the webcast will also be available on the corporate website.

 

 

About EYP-1901
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint’s proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion.

About EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the anticipated use of proceeds for the proposed offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy and the impact of general business and economic conditions, our expectations regarding the timing and clinical development of our product candidates, including EYP-1901; and the potential for EYP-1901 as a novel twice-yearly treatment for serious eye diseases, including wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects

 

 

of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.  

Investors:

Christina Tartaglia
SternIR
Direct: 212-698-8700
christina.tartaglia@sternir.com

 

Media:
Thomas Gibson
201-476-0322
tom@tomgibsoncommunications.com  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

2020

 

2019

 

2020

 

2019

Revenues:

 

 

 

 

 

 

 

 

Product sales, net

 

$              6,680

 

$              7,883

 

$            20,831

 

$            16,824

License and collaboration agreements (including license fees from a related party of $11,500 and $1,030 for the years ended December 31, 2020 and 2019, respectively and $0 during Q4 for both years)

 

                    352

 

                    236

 

               11,942

 

                 1,361

Royalty income

 

                      99

 

                    514

 

                 1,664

 

                 2,180

Total revenues

 

  7,131

 

  8,633

 

  34,437

 

  20,365

Operating expenses:

 

 

 

 

 

 

 

 

Cost of sales, excluding amortization of acquired intangible assets

 

                 2,461

 

                 1,324

 

                 5,824

 

                 2,687

Research and development

 

  5,205

 

  4,131

 

  17,424

 

  15,368

Sales and marketing

 

  5,810

 

  7,399

 

  25,293

 

  29,772

General and administrative

 

  5,777

 

  4,149

 

  20,726

 

  17,939

Amortization of acquired intangible assets

 

  615

 

  615

 

  2,460

 

  2,460

Total operating expenses

 

  19,868

 

  17,618

 

  71,727

 

  68,226

Loss from operations

 

  (12,737)

 

  (8,985)

 

  (37,290)

 

  (47,861)

Other income (expense):

 

 

 

 

 

 

 

 

Interest and other income, net

 

  —

 

  362

 

  58

 

  1,054

Interest expense

 

  (1,827)

 

  (1,787)

 

  (7,257)

 

  (6,176)

Loss on extinguishment of debt

 

  (905)

 

  —

 

  (905)

 

  (3,810)

Total other expense, net

 

  (2,732)

 

  (1,425)

 

  (8,104)

 

  (8,932)

Net loss

 

$          (15,469)

 

$          (10,410)

 

$          (45,394)

 

$          (56,793)

 

 

 

 

 

 

 

 

 

Net loss per common share - basic and diluted

 

$              (1.07)

 

$              (0.98)

 

$              (3.54)

 

$              (5.44)

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding - basic and diluted

 

  14,501

 

  10,688

 

  12,836

 

  10,431

 

 

 

 

 

 

 

 

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands)

 

 

 

December 31,

 

December 31,

 

 

2020

 

2019

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$                 44,909

 

$                 22,214

Accounts and other receivables, net (including due from a related party of $104 and $0 at December 31, 2020 and 2019, respectively)

 

  9,453

 

  11,368

Prepaid expenses and other current assets

 

  3,419

 

  5,997

Inventory

 

  5,337

 

  2,138

Total current assets

 

  63,118

 

  41,717

Property and equipment, net

 

  630

 

  357

Operating lease right-of-use assets

 

  2,610

 

  3,078

Intangible assets, net

 

  25,209

 

  27,669

Restricted cash

 

  150

 

  150

Total assets

 

$                 91,717

 

$                 72,971

Liabilities and stockholders’ equity

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$                   4,811

 

$                   4,192

Accrued expenses

 

  8,445

 

  6,832

Deferred revenue

 

  945

 

  15

Other current liabilities

 

  687

 

  481

Total current liabilities

 

  14,888

 

  11,520

Long-term debt

 

  37,977

 

  47,223

Deferred revenue, less current portion

 

  15,616

 

  —

Operating lease liabilities - noncurrent

 

  2,330

 

  2,898

Other long-term liabilities

 

  2,365

 

  3,000

Total liabilities

 

  73,176

 

  64,641

Stockholders’ equity:

 

 

 

 

Capital

 

  528,380

 

  472,776

Accumulated deficit

 

  (510,680)

 

  (465,286)

Accumulated other comprehensive income

 

  841

 

  840

Total stockholders’ equity

 

  18,541

 

  8,330

Total liabilities and stockholders’ equity

 

$                 91,717

 

$                 72,971

 

 

 

 

 

 GRAPHIC 3 gyzxxuakty5y000001.jpg GRAPHIC begin 644 gyzxxuakty5y000001.jpg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eypt-20210304.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 eypt-20210304_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Incorporation State Country Code Entity Incorporation State Country Code Security 12b Title Security12b Title Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer EX-101.PRE 6 eypt-20210304_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 eypt-8k_20210304_htm.xml IDEA: XBRL DOCUMENT 0001314102 2021-03-04 2021-03-04 false 0001314102 8-K 2021-03-04 EyePoint Pharmaceuticals, Inc. DE 000-51122 26-2774444 480 Pleasant Street Watertown MA 02472 (617) 926-5000 false false false false Common Stock, par value $0.001 EYPT NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information
Mar. 04, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 04, 2021
Entity Registrant Name EyePoint Pharmaceuticals, Inc.
Entity Central Index Key 0001314102
Trading Symbol EYPT
Entity Emerging Growth Company false
Entity File Number 000-51122
Entity Tax Identification Number 26-2774444
Entity Address, Address Line One 480 Pleasant Street
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 926-5000
Entity Incorporation State Country Code DE
Security 12b Title Common Stock, par value $0.001
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports eypt-8k_20210304.htm eypt-20210304.xsd eypt-20210304_lab.xml eypt-20210304_pre.xml eypt-ex991_6.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "eypt-8k_20210304.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "eypt-8k_20210304.htm" ] }, "labelLink": { "local": [ "eypt-20210304_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "eypt-20210304_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "eypt-20210304.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "eypt", "nsuri": "http://eyepointpharma.com/20210304", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "eypt-8k_20210304.htm", "contextRef": "C_0001314102_20210304_20210304", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "eypt-8k_20210304.htm", "contextRef": "C_0001314102_20210304_20210304", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://eyepointpharma.com/20210304/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-21-010712-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-010712-xbrl.zip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end